CD8A and neoplasm: The selectively released Bu also reduced the PD-L1 protein expression in tumor cells (both in vivo and in vitro) via enhanced adenosine 5′-monophosphate-activated protein kinase (AMPK) phosphorylation, resulting in significant increases of CD8+, CD4+, and CD3+ T-cell infiltration in vivo.